Ugur Sahin Sells 31,500 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 31,500 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00. Following the sale, the chief executive officer directly owned 781,709 shares of the company’s stock, valued at approximately $80,922,515.68. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded down $5.10 during trading on Tuesday, reaching $98.66. The company had a trading volume of 1,103,851 shares, compared to its average volume of 1,114,410. The firm has a market capitalization of $24.95 billion, a price-to-earnings ratio of -12.60 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock’s fifty day moving average price is $96.82 and its 200 day moving average price is $95.61. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period in the prior year, the business earned ($1.60) earnings per share. BioNTech’s revenue for the quarter was down 59.5% compared to the same quarter last year. As a group, equities research analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently modified their holdings of BNTX. Larson Financial Group LLC grew its holdings in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. Kennedy Capital Management LLC boosted its position in BioNTech by 0.6% during the fourth quarter. Kennedy Capital Management LLC now owns 21,065 shares of the company’s stock worth $2,005,000 after purchasing an additional 134 shares in the last quarter. Mackenzie Financial Corp grew its holdings in BioNTech by 4.0% in the third quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock valued at $418,000 after purchasing an additional 165 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of BioNTech by 1.0% in the second quarter. Ameriprise Financial Inc. now owns 28,815 shares of the company’s stock valued at $3,068,000 after buying an additional 289 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BNTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Berenberg Bank dropped their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Morgan Stanley cut their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Finally, BMO Capital Markets downgraded BioNTech from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $128.00 to $105.00 in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $126.00.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.